1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Technology Roadmap

1.5. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Development Trends

4. Market Background

4.1. Macro-Economic Factors

4.1.1. Global GDP Growth Outlook

4.1.2. Global Healthcare Spending Outlook

4.2. Forecast Factors – Relevance & Impact

4.2.1. Adoption of Drugs

4.2.2. Disease Prevalence

4.2.3. Reimbursement scenario

4.2.4. Regulatory Scenario

4.2.5. Product in Pipeline

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunity Analysis

5. Market Context

5.1. Drug Type vs Indication Analysis

5.2. Strategic Promotional Analysis, By Key Manufacturers

5.3. Key Regulations

5.4. Porter’s Five Forces Analysis

5.5. PESTLE Analysis

6. COVID19 Crisis Analysis

6.1. Current COVID19 Statistics and Probable Future Impact

6.2. Current GDP Projection and Probable Impact

6.3. Current Economic Projection as compared to 2008 financial analysis

6.4. COVID19 and Impact Analysis

6.4.1. Revenue By Product

6.4.2. Revenue By Dosage Form

6.4.3. Revenue By Country

6.5. 2020 Market Scenario

6.6. Quarter by Quarter Forecast

6.7. Projected recovery Quarter

6.8. Recovery Scenario – Short term, Midterm and Long Term Impact Global

7. Global Eye Infection treatment Market Demand (in Value or Size in US$ Mn) Analysis 2015-2019 and Forecast, 2020-2030

7.1. Historical Market Value (US$ Mn) Analysis, 2015-2019

7.2. Current and Future Market Value (US$ Mn) Projections, 2020-2030

7.2.1. Y-o-Y Growth Trend Analysis

8. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Drug Class

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Drug Class, 2015 – 2019

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2020 – 2030

8.3.1. Antibiotics

8.3.1.1. Sulfonamides

8.3.1.2. Macrolides

8.3.1.3. Erythromycin

8.3.1.4. Chloramphenicol

8.3.1.5. Aminoglycosides

8.3.1.6. Fluoroquinolones

8.3.1.7. Vancomycin

8.3.1.8. Tetracyclines

8.3.2. Antivirals

8.3.2.1. Thymidine-Based Nucleoside Analogues (Trifluridine)

8.3.2.2. Thymidine Phosphorylase Inhibitors (Trifluridine)

8.3.2.3. Acyclic Nucleoside Analogue of 2′Deoxyguanasine (Ganciclovir)

8.3.2.4. Acyclic Guanine Nucleoside Analog (Acyclovir)

8.3.2.5. Others

8.3.3. Antifungals

8.3.3.1. Polyenes (Amphotericin B (AMB) And Natamycin (NTM))

8.3.3.2. Azoles (Miconazole (MCZ), Econazole (ECZ) And Ketoconazole (KCZ))

8.3.3.3. Pyrimidines

8.3.3.4. Echinocandins (Caspofungin (CFG) and Micafungin (MFG))

8.3.3.5. Others

8.3.4. Antihistamines

8.3.5. Corticosteroids

8.3.6. Glucocorticoids

8.4. Market Attractiveness Analysis By Drug Class

9. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Dosage Form

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By Dosage Form, 2015 – 2019

9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Dosage Form, 2020 – 2030

9.3.1. Tablet

9.3.2. Capsule

9.3.3. Ophthalmic Ointment

9.3.4. Eye Drops

9.3.5. Others

9.4. Market Attractiveness Analysis By Dosage Form

10. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Indication

10.1.Introduction / Key Findings

10.2.Historical Market Size (US$ Mn) Analysis By Indication, 2015 – 2019

10.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2020 – 2030

10.3.1. Conjunctivitis

10.3.2. Keratitis

10.3.3. Endophthalmitis

10.3.4. Blepharitis

10.3.5. Stye or Sty (Hordeolum)

10.3.6. Uveitis

10.3.7. Cellulitis

10.3.8. Ocular herpes

10.4.Market Attractiveness Analysis By Indication

11. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Causative Agent

11.1.Introduction / Key Findings

11.2.Historical Market Size (US$ Mn) Analysis By Causative Agent, 2015 – 2019

11.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Causative Agent, 2020 – 2030

11.3.1. Virus

11.3.2. Bacteria

11.3.3. Fungus

11.3.4. Allergens

11.4.Market Attractiveness Analysis By Causative Agent

12. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Distribution Channel

12.1.Introduction / Key Findings

12.2.Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015 – 2019

12.3.Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2020 – 2030

12.3.1. Hospital Pharmacy

12.3.2. Retail Pharmacy

12.3.3. Drug Stores

12.3.4. Online Pharmacy

12.4.Market Attractiveness Analysis By Distribution Channel

13. Global Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030, by Region

13.1.Introduction

13.2.Historical Market Size (US$ Mn) Analysis By Region, 2015 – 2019

13.3.Current Market Size (US$ Mn) Analysis and Forecast By Region, 2020 – 2030

13.3.1. North America

13.3.2. Latin America

13.3.3. Europe

13.3.4. South Asia

13.3.5. East Asia

13.3.6. Oceania

13.3.7. Middle East and Africa (MEA)

13.4.Market Attractiveness Analysis By Region

14. North America Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

14.1. Introduction

14.2. Pricing Analysis

14.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

14.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2020 – 2030

14.4.1. By Country

14.4.1.1. U.S.

14.4.1.2. Canada

14.4.2. By Drug Class

14.4.3. By Dosage Form

14.4.4. By Indications

14.4.5. By Causative Agent

14.4.6. By Distribution Channel

14.5. Market Attractiveness Analysis

14.5.1. By Country

14.5.2. By Drug Class

14.5.3. By Dosage Form

14.5.4. By Indications

14.5.5. By Causative Agent

14.5.6. By Distribution Channel

14.6. Market Trends

14.7. Key Market Participants – Intensity Mapping

14.8. Drivers and Restraints – Impact Analysis

15. Latin America Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

15.1. Introduction

15.2. Pricing Analysis

15.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

15.4. Market Size (US$ Mn) and Volume Forecast By Market Taxonomy, 2020 – 2030

15.4.1. By Country

15.4.1.1. Brazil

15.4.1.2. Mexico

15.4.1.3. Rest of Latin America

15.4.2. By Drug Class

15.4.3. By Dosage Form

15.4.4. By Indications

15.4.5. By Causative Agent

15.4.6. By Distribution Channel

15.5. Market Attractiveness Analysis

15.5.1. By Country

15.5.2. By Drug Class

15.5.3. By Dosage Form

15.5.4. By Indications

15.5.5. By Causative Agent

15.5.6. By Distribution Channel

15.6. Market Trends

15.7. Key Market Participants – Intensity Mapping

15.8. Drivers and Restraints – Impact Analysis

16. Europe Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

16.1. Introduction

16.2. Pricing Analysis

16.3. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

16.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

16.4.1. By Country

16.4.1.1. Germany

16.4.1.2. U.K.

16.4.1.3. France

16.4.1.4. France

16.4.1.5. Italy

16.4.1.6. Spain

16.4.1.7. Russia

16.4.1.8. Rest of Europe

16.4.2. By Drug Class

16.4.3. By Dosage Form

16.4.4. By Indications

16.4.5. By Causative Agent

16.4.6. By Distribution Channel

16.5. Market Attractiveness Analysis

16.5.1. By Country

16.5.2. By Drug Class

16.5.3. By Dosage Form

16.5.4. By Indications

16.5.5. By Causative Agent

16.5.6. By Distribution Channel

16.6. Market Trends

16.7. Key Market Participants – Intensity Mapping

16.8. Drivers and Restraints – Impact Analysis

17. South Asia Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

17.1. Introduction

17.2. Pricing Analysis

17.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 – 2019

17.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

17.4.1. By Country

17.4.1.1. India

17.4.1.2. Thailand

17.4.1.3. Indonesia

17.4.1.4. Malaysia

17.4.1.5. Rest of South Asia

17.4.2. By Drug Class

17.4.3. By Dosage Form

17.4.4. By Indications

17.4.5. By Causative Agent

17.4.6. By Distribution Channel

17.5.Market Attractiveness Analysis

17.5.1. By Country

17.5.2. By Drug Class

17.5.3. By Dosage Form

17.5.4. By Indications

17.5.5. By Causative Agent

17.5.6. By Distribution Channel

17.6.Market Trends

17.7.Key Market Participants – Intensity Mapping

17.8.Drivers and Restraints – Impact Analysis

18. East Asia Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

18.1. Introduction

18.2. Pricing Analysis

18.3. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015 – 2019

18.4. Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

18.4.1. By Country

18.4.1.1. China

18.4.1.2. Japan

18.4.1.3. South Korea

18.4.2. By Drug Class

18.4.3. By Dosage Form

18.4.4. By Indications

18.4.5. By Causative Agent

18.4.6. By Distribution Channel

18.5.Market Attractiveness Analysis

18.5.1. By Country

18.5.2. By Drug Class

18.5.3. By Dosage Form

18.5.4. By Indications

18.5.5. By Causative Agent

18.5.6. By Distribution Channel

18.6 .Market Trends

18.7. Key Market Participants – Intensity Mapping

18.8. Drivers and Restraints – Impact Analysis

19. Oceania Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

19.1.Introduction

19.2.Pricing Analysis

19.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

19.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

19.4.1. By Country

19.4.1.1. Australia

19.4.1.2. New Zealand

19.4.2. By Drug Class

19.4.3. By Dosage Form

19.4.4. By Indications

19.4.5. By Causative Agent

19.4.6. By Distribution Channel

19.5.Market Attractiveness Analysis

19.5.1. By Country

19.5.2. By Drug Class

19.5.3. By Dosage Form

19.5.4. By Indications

19.5.5. By Causative Agent

19.5.6. By Distribution Channel

19.6.Market Trends

19.7.Key Market Participants – Intensity Mapping

19.8.Drivers and Restraints – Impact Analysis

20. Middle East and Africa Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

20.1.Introduction

20.2.Pricing Analysis

20.3.Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2015 – 2019

20.4.Market Size (US$ Mn) Forecast By Market Taxonomy, 2020 – 2030

20.4.1. By Country

20.4.1.1. GCC Countries

20.4.1.2. Turkey

20.4.1.3. Northern Africa

20.4.1.4. South Africa

20.4.1.5. Rest of Middle East and Africa

20.4.2. By Drug Class

20.4.3. By Dosage Form

20.4.4. By Indications

20.4.5. By Causative Agent

20.4.6. By Distribution Channel

20.5.Market Attractiveness Analysis

20.5.1. By Country

20.5.2. By Drug Class

20.5.3. By Dosage Form

20.5.4. By Indications

20.5.5. By Causative Agent

20.5.6. By Distribution Channel

20.6.Market Trends

20.7.Key Market Participants – Intensity Mapping

20.8.Drivers and Restraints – Impact Analysis

21. Emerging Countries Eye Infection treatment Market Analysis 2015-2019 and Forecast 2020-2030

21.1.Introduction

21.1.1. Market Value Proportion Analysis, By Key Countries

21.1.2. Global Vs. Country Growth Comparison

21.2.China Eye Infection treatment Market Analysis

21.2.1. Introduction

21.2.2. Pricing Analysis

21.2.3. PEST Analysis

21.2.4. Market Value Proportion Analysis by Market Taxonomy

21.2.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

21.2.5.1. By Drug Class

21.2.5.2. By Dosage Form

21.2.5.3. By Indications

21.2.5.4. By Causative Agent

21.2.5.5. By Distribution Channel

21.2.6. China Eye Infection treatment Market – Competition Landscape

21.2.7. China – Trade Analysis

21.3.India Eye Infection treatment Market Analysis

21.3.1. Introduction

21.3.2. Pricing Analysis

21.3.3. PEST Analysis

21.3.4. Market Value Proportion Analysis by Market Taxonomy

21.3.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

21.3.5.1. By Drug Class

21.3.5.2. By Dosage Form

21.3.5.3. By Indications

21.3.5.4. By Causative Agent

21.3.5.5. By Distribution Channel

21.3.6. India Eye Infection treatment Market – Competition Landscape

21.4.Brazil Eye Infection treatment Market Analysis

21.4.1. Introduction

21.4.2. Pricing Analysis

21.4.3. PEST Analysis

21.4.4. Market Value Proportion Analysis by Market Taxonomy

21.4.5. Market Value (US$ Mn) Analysis and Forecast by Market Taxonomy

21.4.5.1. By Drug Class

21.4.5.2. By Dosage Form

21.4.5.3. By Indications

21.4.5.4. By Causative Agent

21.4.5.5. By Distribution Channel

21.4.6. Brazil Eye Infection treatment Market – Competition Landscape

22. Market Structure Analysis

22.1.Market Analysis by Tier of Companies (Eye Infection treatment)

22.2.Market Concentration

22.3.Market Share Analysis of Top Players

22.4.Market Presence Analysis

22.4.1. By Regional footprint of Players

22.4.2. Product foot print by Players

22.4.3. Channel Foot Print by Players

23. Competition Analysis

23.1.Competition Dashboard

23.2.Pricing Analysis by Competition

23.3.Competition Benchmarking

23.4.Competition Deep Dive

23.4.1. Allergan plc

23.4.1.1. Overview

23.4.1.2. Product Portfolio

23.4.1.3. Profitability by Market Segments (Product/Channel/Region)

23.4.1.4. Sales Footprint

23.4.1.5. Strategy Overview

23.4.1.5.1. Marketing Strategy

23.4.1.5.2. Product Strategy

23.4.1.5.3. Channel Strategy

23.4.2. Alcon Laboratories, Inc.

23.4.2.1. Overview

23.4.2.2. Product Portfolio

23.4.2.3. Profitability by Market Segments (Product/Channel/Region)

23.4.2.4. Sales Footprint

23.4.2.5. Strategy Overview

23.4.2.5.1. Marketing Strategy

23.4.2.5.2. Product Strategy

23.4.2.5.3. Channel Strategy

23.4.3. Bausch Health Companies Inc.

23.4.3.1. Overview

23.4.3.2. Product Portfolio

23.4.3.3. Profitability by Market Segments (Product/Channel/Region)

23.4.3.4. Sales Footprint

23.4.3.5. Strategy Overview

23.4.3.5.1. Marketing Strategy

23.4.3.5.2. Product Strategy

23.4.3.5.3. Channel Strategy

23.4.4. Pfizer Inc.

23.4.4.1. Overview

23.4.4.2. Product Portfolio

23.4.4.3. Profitability by Market Segments (Product/Channel/Region)

23.4.4.4. Sales Footprint

23.4.4.5. Strategy Overview

23.4.4.5.1. Marketing Strategy

23.4.4.5.2. Product Strategy

23.4.4.5.3. Channel Strategy

23.4.5. Akron Pharma Inc.

23.4.5.1. Overview

23.4.5.2. Product Portfolio

23.4.5.3. Profitability by Market Segments (Product/Channel/Region)

23.4.5.4. Sales Footprint

23.4.5.5. Strategy Overview

23.4.5.5.1. Marketing Strategy

23.4.5.5.2. Product Strategy

23.4.5.5.3. Channel Strategy

23.4.6. Sanofi S.A.

23.4.6.1. Overview

23.4.6.2. Product Portfolio

23.4.6.3. Profitability by Market Segments (Product/Channel/Region)

23.4.6.4. Sales Footprint

23.4.6.5. Strategy Overview

23.4.6.5.1. Marketing Strategy

23.4.6.5.2. Product Strategy

23.4.6.5.3. Channel Strategy

23.4.7. GlaxoSmithKline plc

23.4.7.1. Overview

23.4.7.2. Product Portfolio

23.4.7.3. Profitability by Market Segments (Product/Channel/Region)

23.4.7.4. Sales Footprint

23.4.7.5. Strategy Overview

23.4.7.5.1. Marketing Strategy

23.4.7.5.2. Product Strategy

23.4.7.5.3. Channel Strategy

23.4.8. Intas Pharmaceuticals Ltd

23.4.8.1. Overview

23.4.8.2. Product Portfolio

23.4.8.3. Profitability by Market Segments (Product/Channel/Region)

23.4.8.4. Sales Footprint

23.4.8.5. Strategy Overview

23.4.8.5.1. Marketing Strategy

23.4.8.5.2. Product Strategy

23.4.8.5.3. Channel Strategy

23.4.9. Johnson & Johnson Services, Inc.

23.4.9.1. Overview

23.4.9.2. Product Portfolio

23.4.9.3. Profitability by Market Segments (Product/Channel/Region)

23.4.9.4. Sales Footprint

23.4.9.5. Strategy Overview

23.4.9.5.1. Marketing Strategy

23.4.9.5.2. Product Strategy

23.4.9.5.3. Channel Strategy

23.4.10. Macleods Pharmaceuticals Ltd.

23.4.10.1. Overview

23.4.10.2. Product Portfolio

23.4.10.3. Profitability by Market Segments (Product/Channel/Region)

23.4.10.4. Sales Footprint

23.4.10.5. Strategy Overview

23.4.10.5.1. Marketing Strategy

23.4.10.5.2. Product Strategy

23.4.10.5.3. Channel Strategy

23.4.11. Merck & Co., Inc.

23.4.11.1. Overview

23.4.11.2. Product Portfolio

23.4.11.3. Profitability by Market Segments (Product/Channel/Region)

23.4.11.4. Sales Footprint

23.4.11.5. Strategy Overview

23.4.11.5.1. Marketing Strategy

23.4.11.5.2. Product Strategy

23.4.11.5.3. Channel Strategy

23.4.12. Mylan N.V.

23.4.12.1. Overview

23.4.12.2. Product Portfolio

23.4.12.3. Profitability by Market Segments (Product/Channel/Region)

23.4.12.4. Sales Footprint

23.4.12.5. Strategy Overview

23.4.12.5.1. Marketing Strategy

23.4.12.5.2. Product Strategy

23.4.12.5.3. Channel Strategy

23.4.13. Teva Pharmaceutical Industries Ltd.

23.4.13.1. Overview

23.4.13.2. Product Portfolio

23.4.13.3. Profitability by Market Segments (Product/Channel/Region)

23.4.13.4. Sales Footprint

23.4.13.5. Strategy Overview

23.4.13.5.1. Marketing Strategy

23.4.13.5.2. Product Strategy

23.4.13.5.3. Channel Strategy

24. Assumptions and Acronyms Used

25. Research Methodology

【免責事項】
https://www.marketreport.jp/reports-disclaimer